A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03709316 |
Recruitment Status : Unknown
Verified May 2021 by Zai Lab (Hong Kong), Ltd. ( Zai Lab (Shanghai) Co., Ltd. ).
Recruitment status was: Active, not recruiting
First Posted : October 17, 2018
Last Update Posted : June 2, 2021
|
Sponsor:
Zai Lab (Shanghai) Co., Ltd.
Information provided by (Responsible Party):
Zai Lab (Hong Kong), Ltd. ( Zai Lab (Shanghai) Co., Ltd. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | January 29, 2022 |
Estimated Study Completion Date : | December 30, 2023 |